focus -WSS

focus

author：entertainment 2025-09-28 00:49:08 - browse：25261

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： SCOTUS to consider access to abortion pill mifepristone

WSS

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Feed a cold, starve a fever? Here’s what science says

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Doctors are clamoring for more clarity on Paxlovid prescribing

After sickle

Pfizer plans to depart BIO

hotspot

focus

entertainment

Activists slam private health insurers over coverage restrictions

CMS should re

Moonlake's readout produced a cash windfall. Risks remain

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Hollywood unions extend contract negotiations for actors

AI models in health care face new federal disclosure requirements

What does generative AI mean for health care? We asked experts

Chemotherapy shortages won’t get better under Biden’s latest plan

Duchenne breakthrough therapy leaves behind pioneering families

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

focus

'Brian's Song' at 50 still offers lessons about cancer for today

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Chemotherapy shortages won’t get better under Biden’s latest plan

AI models in health care face new federal disclosure requirements

What causes an itch? Researchers may have solved the mystery

FDA approves world's first CRISPR

Wikipedia

hotspot

hotspot

leisure time